Cibus (CBUS) Debt-to-Equity : 0.08 (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Cibus Debt-to-Equity?

Cibus's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $6.66 Mil. Cibus's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $16.21 Mil. Cibus's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $278.22 Mil. Cibus's debt to equity for the quarter that ended in Mar. 2024 was 0.08.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cibus's Debt-to-Equity or its related term are showing as below:

CBUS' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.06 Med: 0.3 Max: 5.53
Current: 0.08

During the past 9 years, the highest Debt-to-Equity Ratio of Cibus was 5.53. The lowest was 0.06. And the median was 0.30.

CBUS's Debt-to-Equity is ranked better than
63.92% of 1081 companies
in the Biotechnology industry
Industry Median: 0.15 vs CBUS: 0.08

Cibus Debt-to-Equity Historical Data

The historical data trend for Cibus's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cibus Debt-to-Equity Chart

Cibus Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.30

0.54

1.27

1.92

0.08

Cibus Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															5.53	0.06	0.06	0.08	0.08

Competitive Comparison of Cibus's Debt-to-Equity

For the Biotechnology subindustry, Cibus's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cibus's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cibus's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cibus's Debt-to-Equity falls into.

Cibus Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cibus's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(6.947	+	17.674)	/	293.47
	=	0.08

Cibus's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(6.663	+	16.209)	/	278.217
	=	0.08

Cibus (NAS:CBUS) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Cibus Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Cibus's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cibus (CBUS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cibus Inc (NAS:CBUS) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

6455 Nancy Ridge Drive, San Diego, CA, USA, 92121

Website

https://www.cibus.com

Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies.

Executives

Rory B Riggs	director, officer: Chief Executive Officer	65 RAILROAD AVE, RIDGEFIELD NJ 07657
Collins James C. Jr.	director	1007 MARKET STREET, D-9058, WILMINGTON DE 19898
Jonathan Finn	10 percent owner	C/O VANTAGE CONSULTING GROUP, INC., 3500 PACIFIC AVENUE, VIRGINIA BEACH VA 23451
Gerhard Prante	director	SCHONE AUSSICHT 5, HOFHEIM A. TS 2M 65719
Mark Terrence Finn	director	VANTAGE CONSULTING GROUP, INC., 3500 PACIFIC AVENUE, VIRGINIA BEACH VA 23451
Jean-pierre Jules Lehmann	director	21 ALPINASTRASSE, CH 3780, GSTAAD V8 3780
Keith Allen Walker	director	13315 ROXTON CIRCLE, SAN DIEGO CA 92130
Wade Hampton King	officer: Chief Financial Officer	750 MEADOWOOD DRIVE, ASPEN CO 81611
Gocal Gregory Francis William	officer: See Remarks	13737 BASSMORE DR., SAN DIEGO CA 92129
Peter Beetham	director, officer: See Remarks	6455 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Yves J Ribeill	director	C/O CALYXT, INC., 2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113
Michael A. Carr	director, officer: President and CEO	2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113
William Koschak	officer: Chief Financial Officer	2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113
Sarah Reiter	officer: Chief Business Officer	202 COUSTEAU PLACE, DAVIS CA 95618
Daniel F Voytas	officer: Chief Science Officer	2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113